在中国免费用twitter加速软件
logo_new@0,75x

手机怎么浏览国外网站

手机怎么浏览国外网站

Our technology could revolutionize care and treatment for people at risk due to chronic liver disease—both people with viral hepatitis (chronic hepatitis B and C infections) and the rapidly growing population with non-viral hepatitis due to obesity and metabolic disease.

手机怎么浏览国外网站

Glycotest blood tests are being developed to provide information on the likelihood of serious liver disease like cancer or fibrosis-cirrhosis by employing technology designed to measure two kinds of disease signals:

» The amount of the monosaccharide fucose that appears abnormally on certain serum glycoproteins—to indicate likelihood of disease.

» The pattern of glycoproteins that is abnormally fucosylated—to monitor specific diseases like HCC, CCA or fibrosis-cirrhosis.

Novel Disease Signals

Proprietary biomarkers and assays based on glycoproteins with sugars that are abnormally altered in liver disease.

Non-invasive Blood Tests

Algorithm-driven biomarker panels that use standard blood samples to measure likelihood of liver disease.

Early Detection

Early detection of curable liver cancer and other liver diseases to improve patient outcomes.

手机怎么浏览国外网站

- Exploits unique disease signal chemistry (glycoprotein fucosylation) present in liver cancers and fibrosis-cirrhosis but absent in healthy individuals

- Incorporated into highly promising biomarker panels

- Focused on the detection of potentially curable early-stage disease

- May outperform currently available serum biomarkers, such as AFP

- Targeting the worldwide liver cancer threat that kills more than 700,000 people annually and is the fastest growing cause of cancer death in the US

LATEST NEWS

Glycotest, Inc. Receives $3 Million Second Tranche of $10 Million Series A Financing

November 21, 2019
-
News

New York, NY—November 21, 2019.  Glycotest, Inc., a diagnostics company commercializing new and unique blood tests for life threatening liver cancers and fibrosis–cirrhosis, announced today that the Company …

Read More →
3 MIN READ

Glycotest is developing a new Test for Detecting Early Stage Liver Cancer with the revolutionary approach of using Glycoproteins as Biomarkers – CEOCFO Magazine

September 3, 2019
-
在中国免费用twitter加速软件

Glycotest19-CEOCFOMagazine-Interview.pdf

在中国免费用twitter加速软件
在中国免费用twitter加速软件

Glycotest was chosen as one of 50 companies to be in the MedTech Showcase in September 2019

August 22, 2019
-
News

MedTech Innovator Showcase Announcement 6.17.19

Read More →
1 MIN READ
SEE MORE

GLYCOTEST INTRODUCTION

A New Paradigm for Early Diagnosis and Surveillance For Liver Cancer

在中国免费用twitter加速软件
Glycotest | Glycotest Diagnostics